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Abstract: The treatment of breakthrough pain (BTP), a transitory exacerbation of pain that occurs on a background of otherwise-controlled, 
persistent pain, requires an opioid formulation and/or method of administration that can provide rapid and extensive systemic exposure. 
Fentanyl buccal tablet (FBT; FENTORA®, Cephalon, Inc.) employs OraVescent® drug delivery technology, which enhances the rate and 
extent of fentanyl absorption. OraVescent technology enhances the oral dissolution and buccal absorption of fentanyl, which facilitates 
rapid uptake of fentanyl into the bloodstream, reducing gastrointestinal absorption and minimizing extensive first-pass metabolism. The 
resulting pharmacokinetic profile of FBT is characterized by greater bioavailability and a higher early systemic exposure compared with 
the earlier oral transmucosal fentanyl citrate formulation. In clinical studies of opioid-tolerant patients with cancer-related and noncancer-
related BTP, FBT has provided consistent and clinically relevant improvements in pain intensity and pain relief relative to placebo, with a 
safety and tolerability profile that is generally typical of that observed with other potent opioids. The pharmacokinetic properties of FBT 
allow for meaningful clinical efficacy, with an onset of action that closely matches the onset of BTP.
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Introduction: Breakthrough pain
Breakthrough pain (BTP) is a transitory exacerbation 
of  pain  that  occurs  on  a  background  of  chronic, 
  persistent pain that is otherwise controlled by around-
the-clock  (ATC)  opioids.1–3  Much  of  the  medical 
literature  surrounding  BTP  comes  from  studies  of 
patients with cancer-related pain in which the BTP 
was characterized as rapidly escalating, often reaching 
peak intensity within minutes.1,2 In a landmark survey 
of  164  patients  with  controlled,  persistent  cancer-
related pain, the median onset to peak BTP intensity 
was reported to be 3 minutes, with patients experienc-
ing a median 6 episodes each day.2 In a more recent 
survey that reported on the prevalence and charac-
teristics of BTP in 228 opioid-treated patients with 
controlled, persistent noncancer pain, most patients 
(74%) had BTP, which reached maximum intensity 
in a median of 10 minutes; patients experienced a 
median  of  2  episodes  per  day.4  Over  700  patients 
were screened for this survey and the majority did not 
have controlled persistent pain, highlighting the need 
for better pain management.
A common practice in managing BTP in patients 
who are taking ATC opioids is to add supplemental 
short-acting opioids (e.g. immediate-release morphine, 
hydrocodone, oxycodone) to the chronic pain treatment 
regimen. These medications, however, typically require 
at least 30 minutes or more to begin to take effect,3,5 
which is often not fast enough to alleviate BTP. In the 
study of BTP in association with chronic noncancer 
pain, in which most patients were taking short-acting 
opioids for BTP, 65% of patients reported that their BTP 
did not respond consistently to the interventions used.4 
Fentanyl buccal tablet (FBT; FENTORA®, Cephalon, 
Inc.),6 offers a potential advantage in this respect, in 
that  its  pharmacokinetic  and  analgesic  profile  more 
closely matches the time to onset of BTP.
Transmucosal Administration of 
Fentanyl for the Management of BTp
The  toxicology,  pharmacological  effects,  and 
  mechanism  of  action  of  fentanyl,  a  potent  µ-opi-
oid  receptor  agonist,  have  been  characterized 
  extensively, and fentanyl has become one of the most 
widely prescribed opioids for chronic and periopera-
tive pain management.7 When given intravenously, 
the  highly  lipophilic  fentanyl  readily  crosses  the 
blood-brain barrier, quickly entering into the central 
  nervous system.8,9 However, when given orally, fen-
tanyl is absorbed through the gastrointestinal tract and 
undergoes extensive intestinal and hepatic first-pass 
metabolism, making it less bioavailable than fentanyl 
delivered intravenously.10,11 To relieve BTP effectively 
in an outpatient setting, delivery of fentanyl requires 
a formulation and/or method of administration that 
can provide rapid and extensive systemic exposure.
The  oral  mucosa  is  an  attractive  route  for  drug 
delivery because it is easily accessible, is more perme-
able than skin (because of its nonkeratinized epithelia), 
has a rich blood supply, and allows fentanyl to avoid 
first-pass metabolism.12,13 The lipophilicity of fentanyl 
allows it to pass readily through the buccal mucosa.
Oral transmucosal fentanyl citrate (OTFC®, Actiq®, 
Cephalon,  Inc.)  was  the  first  rapid-onset  opioid 
  introduced for pain management. OTFC is indicated 
for the treatment of cancer-related BTP in patients 
who  are  already  receiving  and  who  are  tolerant  to 
opioid therapy for their underlying persistent cancer 
pain; OTFC is contraindicated in opioid non-tolerant 
patients and in the management of acute or postopera-
tive pain including headache/migraine.14 Formulated 
as a sweetened lozenge on a stick, OTFC is designed 
to dissolve slowly in the mouth; patients use the han-
dle to move the lozenge from one side of the mouth to 
the other to “paint” the mucosa with the medication. 
Administered in this manner, OTFC was shown to 
increase the rate and extent of absorption of fentanyl 
compared with orally administered fentanyl.11
Although  the  lipophilicity  of  fentanyl  allows 
it  to  pass  readily  through  the  buccal  mucosa,  this 
same  characteristic  renders  it  less  soluble  in  an 
  aqueous solution, such as saliva.15 As Durfee et al 
have observed, fentanyl is a weak base, and dissolu-
tion requires a relatively low pH, where the ionized, 
  hydrophilic form of the drug predominates. In con-
trast, permeation and absorption of fentanyl through 
a  cellular  membrane,  such  as  the  buccal  mucosa, 
requires a higher pH, where the nonionized, lipophilic 
form of the drug predominates.15
FBT  is  a  novel  formulation  of  transmucosal 
  fentanyl citrate. It uses OraVescent® technology to 
further  increase  the  rate  and  extent  of  absorption 
of fentanyl provided by its predecessor compound, 
OTFC.16 FBT is indicated for the treatment of cancer-
related BTP in patients who are already receiving and 
who are tolerant to opioid therapy for their underlying Fentanyl buccal tablet for breakthrough pain
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  persistent  cancer  pain;  FBT  is  contraindicated  in 
opioid non-tolerant patients and in the management 
of acute or postoperative pain including headache/
migraine.6  Aspects  of  the  OraVescent  delivery 
  system are described in detail below.
OraVescent® Technology
OraVescent  technology  was  developed  to  enhance 
drug delivery, using fentanyl as the test compound. It 
was hypothesized that the clinical efficacy of fentanyl 
might  be  enhanced  if  the  delivery  system  could 
improve dissolution and passage of the drug into the 
circulation by selectively modifying the local pH and 
permeability at the mucosal wall. An initial decrease 
in pH would promote the soluble, ionized, hydrophilic 
form of fentanyl, and a subsequent, gradual increase in 
pH would promote the more absorbable, nonionized, 
lipophilic form. Also, the liberation of carbon diox-
ide (CO2) has been shown in animal tissue to increase 
the  permeability  of  epithelial  barriers  by  altering 
  paracellular pathways, enhancing drug penetration.17 
These characteristics describe the broad mechanism 
of action of the OraVescent tablet. The approved FBT 
formulation  contains  sodium  bicarbonate,  sodium 
carbonate, and citric acid, which induce the required 
sequence of pH changes and an accompanying libera-
tion of CO2.15
A hypothesis explaining how the different reac-
tions involved in the dissolution of tablets via the 
  OraVescent  system  induce  pH  changes  has  been 
  published  elsewhere;  the  reactions  are  shown  in 
  Figure 115 and Table 1.18 In brief, as the tablet begins to 
dissolve, the local environment becomes more acidic 
because of the dissolved citric acid and CO2. In this 
acidic environment, the available fentanyl becomes 
almost completely ionized and, therefore, its aque-
ous solubility is high. As the reactions progress, CO2 
is released and the pH increases in the presence of a 
larger number of basic cations, rendering the dissolved 
fentanyl nonionized. Concurrently, the accompany-
ing CO2 liberation is thought to improve membrane 
permeation of fentanyl. As the pH increases, a physi-
ological “pump,” caused by the local concentration 
gradient  of  nonionized  fentanyl,  is  created,  which 
pushes the drug into and across the lipid barrier of the 
buccal mucosa.15,18
A preliminary, open-label pharmacokinetic study 
that  compared  FBT  with  OTFC  highlighted  the 
potential of OraVescent technology.19 In this study, 
12 healthy men were randomized to receive one of 
three treatments: OraVescent FBT, non-OraVescent 
FBT (a tablet containing fentanyl and lactose in place 
of the OraVescent components), or OTFC. Subjects 
who received OraVescent FBT had an increased peak 
serum fentanyl concentration (Cmax), a shorter time to 
reach Cmax (tmax), and a larger area under the serum 
fentanyl concentration-vs.-time curve compared with 
those who received OTFC or non-OraVescent FBT 
(Table 2). Fentanyl was absorbed more rapidly and 
induced  greater  systemic  exposure  when  coupled 
with OraVescent technology than with either of the 
other fentanyl formulations (Fig. 2).19
M
e
a
n
 
p
H
Time (min)
Citric acid (H3Ct) ↓pH,
↑fentanyl solubility
7.5
7.0
6.5
6.0
5.5
4.5
5.0
0 1 2 3 4 5
CO2 effervescence  ↑membrane penetration, and continues to  ↑pH
NaHCO3 + Na2CO3 released, ↑buccal pH
Figure 1. Changes in pH over the surface of the dissolving fentanyl buccal tablet during the initial 5-minute time interval. Adapted with permission from   
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Table 1. Reactions occurring during Oravescent® tablet dissolution and absorption.
Reaction Activity pH effect
Citric acid (H3Ct) dissolves in aqueous 
solution
pH↓
Sodium bicarbonate (NaHCO3)  
solid (s) dissolves, leaving  
bicarbonate (HCO3
−) in solution
Decreased pH shifts solid (s) drug (D) 
to ionized form and it becomes  
soluble (aq); liquid is formed (H2O(l))
Bicarbonate neutralizes acid and  
releases CO2 gas (g)
pH↑
increased pH leads to unionized and 
absorbable form of drug (D(aq))
Adapted with permission from Hamed and Durfee.18
H O H Ct H O H Ct 2 3 3 2 +  →  +
←  
+ −
NaHCO s Na HCO 3 3 ( ) ←  
+ −  →  +
D s H O D aq H O HD aq
H O l
( ) ( ) ( )
( )
+  →  +  → 
+
+
←  
+
←  
+
3 3
2
( ) ( ) 1 2 3 3 2 2 H O HCO H O CO aq
+ −
←   +  →  +
( ) ( ) ( ) 2 2 2 CO aq CO g ←    → 
Table 2. early study of fentanyl pharmacokinetics following administration of Oravescent® FBT vs. Non-Oravescent® FBT 
and OTFC® in healthy volunteers.
OraVescent® FBTa non-OraVescent® FBT OTFc®
Cmax (ng/mL)
  Mean (SD) 0.6412 (0.2804) (P  0.0003) 0.3986 (0.0744) 0.4073 (0.1537)
AUC0-t (ng•h/mL)
  Mean (SD) 2.656 (0.6729) (P  0.01) 2.041 (0.8690) 1.809 (0.9358)
tmax (h)
  Median 0.501 (P  0.003) 2 2
Adapted with permission from Pather et al19 and data on file (Cephalon, Inc.).
aDifferences between Oravescent® FBT and non-Oravescent® FBT/OTFC were statistically significant (P  0.05) for Cmax, AUC0-t and tmax.
Abbreviation: AUC0-t = area under the serum fentanyl concentration-vs.-time curve from time 0 to the time of the last measurable concentration (t).
HD aq OH D aq H O l
+ −
←   +  →  + ( ) ( ) ( ) 2
These preliminary findings were supported by an 
additional  randomized,  open-label,  crossover  study 
of healthy adults that assessed the bioavailability of 
fentanyl delivered using FBT and OTFC (Table 3).16 
The study showed that OraVescent technology more 
than doubled the portion of the fentanyl dose absorbed 
via the buccal mucosa (48% with FBT vs. 22% with 
OTFC). This  resulted  in  greater  absolute  bioavail-
ability of FBT than OTFC (65% vs. 47%) and more 
rapid absorption into the systemic circulation (tmax: 47 
minutes for FBT vs. 91 minutes for OTFC). Because 
of the improvement in the extent and speed of absorp-
tion afforded by the OraVescent technology, the early 
systemic exposure (i.e. the area under the plasma drug 
concentration-vs.-time curve [AUC] from time 0 to 
tmax [AUC0-tmax]) to fentanyl exceeded that provided 
by OTFC (0.40 vs. 0.14 ng•h/mL) (Fig. 3, Table 3).16
Because  of  these  pharmacokinetic  differences 
between the formulations, it should be noted that the 
clinical dose ratio of FBT to OTFC is not 1:1. Based 
on the study presented above, a dose of FBT up to 30% 
smaller than one of OTFC would be expected to result 
in comparable levels of systemic fentanyl exposure.16
The pharmacokinetics of FBT
A number of studies have been performed to describe 
the  pharmacokinetic  properties  of  FBT.20–23  These 
studies have shown that the AUC of fentanyl deliv-
ered by FBT is characterized by the rapid absorp-
tion of fentanyl into the systemic circulation (Fig. 2 
and 3).16,19 This is followed by a triexponential decline 
from Cmax, which represents a rapid distribution of 
fentanyl from blood into highly perfused tissues (i.e. 
the brain, heart, and lungs); second, elimination and Fentanyl buccal tablet for breakthrough pain
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absorption of the swallowed portion of fentanyl in the 
intestinal tract; and, finally, the redistribution of fen-
tanyl to the deep tissue compartments (i.e. muscle and 
adipose tissue) and subsequent elimination.23 Plasma 
  concentrations  of  FBT  are  generally  maintained 
within 80% of Cmax from 20 minutes to 2 hours.20–23
The median tmax of fentanyl obtained with FBT has 
been shown to be approximately 50 minutes and has 
been consistent following single and multiple dos-
ing studies.20–23 Early systemic exposure (AUC0-tmax 
of 100 µg [i.e. the reference dose] [AUC0-tmax′]) and 
overall  systemic  exposure  (measured  by  Cmax  and 
AUC from time zero extrapolated to infinity [AUC0-∞]) 
increased approximately linearly across the therapeu-
tic dose range (100–800 µg).21 This suggests that FBT 
can be reliably titrated within the therapeutic dose 
range (100–800 µg) for patients who require doses at 
the upper end of that range.20–22 More recently, FBT 
was shown to be dose proportional up to 1300 µg.24
The time it takes for FBT to disappear completely 
once  placed  in  the  buccal  cavity  (i.e.  the  “dwell 
time”) varies among patients. Therefore, data from 
two  open-label  studies20,22  were  analyzed  to  deter-
mine  if  dwell  time  affected  the  pharmacokinetic 
properties  of  FBT,  specifically  absorption.25  Mean 
dwell times ranged from 14 to 25 minutes, with no 
apparent relationship to dose.25 It is important to note 
that there was no evidence of an association between 
dwell time and dose-normalized Cmax (means 0.42–
0.66  pg/mL/200  µg),  dose-normalized  AUC0-tmax′ 
  (means 0.24–0.38 pg•h/mL/200 µg), or tmax (medians 
45–60  minutes),  suggesting  that  any  remaining 
portion of the tablet contains little or no fentanyl and 
probably consists of the residue of excipients.25
Sublingual placement of FBT has been explored 
as an alternative to buccal placement. A study among 
90 healthy volunteers showed that median tmax (range) 
values were similar after buccal and sublingual admin-
istration: 0.75 hours (0.33–3.13 hours) and 0.78 hours 
(0.17–3.00 hours), respectively.26 Drug concentration-
vs-time plots were similar for the two administration 
sites, with comparisons of AUC0-∞ and Cmax meeting 
the criteria for bioequivalence. Oral inspection 15 and 
30 minutes after FBT placement showed that fewer 
subjects had residue following sublingual compared 
with  buccal  placement.  This  may  suggest  that  the 
larger volumes of saliva available sublingually may 
help to dissolve the tablet excipients. Indirectly, this 
also provides support for the premise that dwell time 
does not affect the absorption of fentanyl. Overall 
incidences of application site adverse events (AEs) 
were similar for the two placement options. Thus, 
sublingual FBT placement is an alternative to buccal 
placement in patients who prefer sublingual admin-
istration or require an alternative application site, for 
example, because of dentures, cancer-related mucosi-
tis, or the need for caregivers to place the tablet.26
clinical Outcomes with FBT
The analgesic effects of FBT have been evaluated 
in clinical studies of BTP in opioid-tolerant patients 
suffering from chronic persistent cancer and noncan-
cer pain.27–31 These studies provide evidence for the 
efficacy, safety, and tolerability profile of FBT in the 
management of BTP.
Initially, FBT was studied in patients with chronic 
cancer-related BTP. The evidence for the effectiveness 
of  FBT  in  this  indication  is  based  primarily  on 
two  similarly  designed,  placebo-controlled  stud-
ies  of  opioid-tolerant  patients  with  chronic  cancer 
pain experiencing one to four episodes of BTP per 
day.28,31 The criterion used for opioid tolerance was a 
dose of 60 mg of oral morphine/day, or an equiva-
lent (in analgesic effect) dose of another opioid for 
7 days prior to enrollment. After FBT was titrated 
to an effective dose in each patient, patients were   
randomized to a blinded sequence of 10 treatments 
(seven FBT, three placebo) to be taken for 10 con-
secutive BTP episodes. Patients continued to receive 
Table 3. Pharmacokinetic parameters of FBT and OTFC® 
in healthy volunteers.
FBT 400 µg OTFc®a
Cmax (ng/mL)
  Mean (SD) 1.02 (0.42) 0.63 (0.21)
AUC0–∞ (ng•h/mL)
  Mean (SD) 6.48 (2.98) 4.79 (1.96)
AUC0–tmax (ng•h/mL)
  Mean (SD) 0.40 (0.18) 0.14 (0.05)
tmax (minutes)
  Median (range) 46.8  
(20.0–240.0)
90.8 
(35.0–240.1)
Darwish M, Kirby M, Robertson P Jr, et al. Journal of Clinical Pharmacology. 
(vol 47, issue 3) p. 343–350. Copyright © 2007 by SAGe Publications. 
Reprinted by permission of SAGe Publications.16
aDose-normalized to 400 µg, except for tmax.Fentanyl buccal tablet for breakthrough pain
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their ATC opioid therapy and were allowed to take 
their  prestudy  supplemental  drugs  if  they  did  not 
achieve satisfactory relief within 30 minutes of FBT 
administration. Patients rated their pain intensity (PI) 
before, and PI and pain relief (PR) after, each admin-
istration of the study drug for a BTP episode. The pri-
mary efficacy variable was the sum of PI differences 
(SPID) 30 and 60 minutes after treatment in Portenoy 
et al28 and Slatkin et al,31 respectively.
Similar  results  were  seen  in  both  studies:  both 
showed consistent and clinically relevant improve-
ments in PI and PR with FBT.28,31 The primary effi-
cacy objective was achieved in both cases (study 1: 
SPID30, FBT vs. placebo, least squares mean [SEM]: 
3.0 ± 0.12 vs. 1.8 ± 0.18; study 2: SPID60, FBT vs. 
placebo, mean [SE]: 9.7 ± 0.63 vs. 4.9 ± 0.50; both 
P  0.0001). In the second of the two studies, which 
provided a more comprehensive assessment over time 
of the analgesic effects of FBT relative to placebo 
(5–120  minutes  post  dose),  analgesic  activity  with 
FBT was observed as early as 10 minutes following 
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Figure 4. effect of fentanyl buccal tablet (FBT) (black square) and placebo (white triangle) on pain scores in opioid-tolerant patients with breakthrough 
pain (BTP) associated with chronic cancer pain (n = 78): A) pain intensity difference B) pain relief. This figure was published in The Journal of Supportive 
Care, 5, Slatkin Ne, Xie F, Messina J, Segal TJ, Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic 
pain. p. 327–334. Copyright elsevier (2007).31
*P  0.0001.
buccal placement (Fig. 4).31 At 10 minutes post dose, 
there  were  significantly  greater  reductions  in  PI 
(Fig. 4A) and significantly greater improvements in 
PR scores (Fig. 4B) during BTP episodes treated with 
FBT  vs.  placebo  (P    0.0001).  These  differences 
increased over time through 60 minutes and were then 
maintained through 2 hours. In addition, the propor-
tion of episodes with a clinically relevant reduction in 
PI (33%)32 was significantly (P  0.05) greater with 
FBT versus placebo at all time points from 10 through 
120 minutes. Additional supplemental medication was 
taken by patients for a smaller percentage of episodes 
treated with FBT vs. placebo (11% vs. 30%).31
To date, the clinical study program for FBT has 
also included three double-blind, placebo-controlled 
efficacy studies in opioid-tolerant patients with BTP 
in association with chronic noncancer-related pain. 
Two of the noncancer studies, which enrolled patients 
with chronic low back pain29 and neuropathic pain,30 
were similar in design to the aforementioned cancer 
studies; the third enrolled patients with a range of Darwish et al
18  Perspectives in Medicinal Chemistry 2010:4
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Table 5. Adverse event profile of FBT during short-term clinical studies.28–31
Aes cancer patients noncancer patients
portenoy et al 2006  
(n = 123), n (%)
slatkin et al 2007  
(n = 125), n (%)
simpson et al 2007  
(n = 102), n (%)
portenoy et al 2007 
(n = 104), n (%)
Total Aes NR 83 (66) 64 (63) 68 (65)
Discontinuations due  
  to Aes
15 (12) 19 (15) 12 (12) 12 (12)
Serious Aes 14 (11)a 11 (9)b 1 (1)c 2 (2)d
Aes most frequently  
  reportede
Application site Aes 2 (2)f 12 (10) 8 (8) 6 (6)
Asthenia 9 (7) – – –
Constipation 10 (8) 7 (6) – –
Dizziness 27 (22) 14 (11) 13 (13) 14 (13)
Dry mouth – – – 5 (5)
Dysgeusia – – – 8 (8)
Fatigue 15 (12) 10 (8) – –
Headache 18 (15) 8 (6) – –
Nausea 27 (22) 16 (13) 13 (13) 20 (19)
Somnolence 12 (10) – 10 (10) 9 (9)
vomiting 13 (11) 8 (6) 5 (5) 6 (6)
aAll related to patients’ underlying conditions; seven deaths attributable to disease progression occurred during the study.
bAll related to disease progression; nine deaths attributable to progression of the underlying cancer occurred during the study.
cAngina pectoris, unrelated to study medication.
dDiabetic gastroparesis (relationship to treatment not reported) and accidental overdose resulting in loss of consciousness (patient took 4 x 600 µg tablets 
without explanation, and recovered fully when revived with oxygen).
ein 5% (Portenoy et al 2006) and 5% (Slatkin et al 2007; Simpson et al 2007; Portenoy et al 2007) of patients.
fOnly application site ulcers of the oral mucosa were reported.
Abbreviation: NR, not reported.
chronic noncancer pain conditions and had a novel, 
12-week design.27
Consistent results were seen across the noncancer 
studies: the primary efficacy variable—SPID60—was 
significantly greater (P  0.05) with FBT than with 
placebo (Table 4).27,29,30 Analgesic efficacy was seen as 
early as 5 minutes for some measures and effects were 
maintained for the 120-minute duration of evaluation, 
which is consistent with the findings of the cancer 
studies. In general, patients resorted to supplemental 
medication for nearly three times as many episodes of 
BTP treated with placebo as with FBT.29,30
Safety and Tolerability Profile of FBT 
in clinical studies of BTp
Experience  to  date  has  suggested  that  the  safety 
and  tolerability  profile  of  FBT  is  generally  simi-
lar to that of other potent opioids.8,9,33 In the short-
term studies with FBT, in both cancer and noncancer 
patient populations, the most frequent AEs included 
nausea,  vomiting,  headache,  dizziness,  and  fatigue 
(Table  5).28–31  These  AEs  were  generally  mild  to 
moderate in intensity. Application site AEs, related 
to the buccal placement of FBT, occurred in up to 
10% of patients. The majority of these were mild and 
transient and did not lead to discontinuation of study 
drug. In the cancer studies, up to 11% of patients 
experienced a serious AE; none were considered by 
the investigator to be related to study medication.28,31 
In the noncancer studies, three patients experienced a 
serious AE; one event (nonfatal overdose resulting in 
loss of consciousness) was considered by the investi-
gator to be related to study medication.29,30
The  most  commonly  reported  AEs  in  the 
12-week study in patients with noncancer-related BTP 
included nausea (15%), dizziness (11%), somnolence 
(8%), vomiting (5%), and arthralgia (5%), which were 
similar to the AEs observed in the short-term studies. 
Application site AEs were reported in 7% of patients. 
Ten of 148 patients (7%) had one or more serious AEs 
during the study; most were considered not related to 
treatment. One patient developed pneumonia and had 
an accidental overdose of opioid medication; how-
ever,  the  relative  contribution  of  study  medication Darwish et al
20  Perspectives in Medicinal Chemistry 2010:4
or other opioids to these events was unknown. One 
patient reportedly consumed all of her opioid medi-
cation (FBT, oxycodone, and oxycocet) over a short 
period of time and began suffering from withdrawal 
symptoms after finishing her medications.27
The longer-term safety and tolerability profile of 
FBT has been investigated in an open-label extension 
study  among  patients  with  cancer-related  chronic 
pain and BTP for treatment periods of 12 months or 
  longer.34 A  total  197  opioid-tolerant  patients  were 
exposed to FBT for a median 122 days (range, 1–698). 
  During the period when patients were maintained on 
their individual effective doses, 71 patients stopped 
treatment with FBT because of AEs. In general, these 
AEs were consistent with those observed in the short-
term  studies  and  included  nausea,  vomiting,  and 
  dizziness. All of the serious AEs were considered to 
be unrelated to study medication by the investigators, 
with one exception (drug withdrawal syndrome).34
Data  are  also  available  for  728  opioid-toler-
ant patients with noncancer-related BTP treated for 
a median (range) 329 (1–638) days.35 During long-
term follow up (n = 646), the most common AEs 
were  nausea  (17%  of  patients),  back  pain  (15%), 
vomiting  (12%),  and  headache  (11%). There  were   
118 patients (18%) with one or more serious AEs; 
the most common serious AEs were chest pain, pneu-
monia, and vomiting (five patients each). Six deaths 
occurred  (three  myocardial  infarction,  two  cardiac 
arrest, one pneumonia); all were rated by investiga-
tors as not or unlikely to be related to FBT. There 
were two reports of accidental overdose; nine patients 
reported AEs associated with opioid overdose (ATC 
and/or FBT and/or other medications). Factors lead-
ing to these events included suicide attempt, altered 
mental  status,  and  aberrant  drug-related  behaviors. 
There was also one case of study drug diversion. Drug 
withdrawal syndrome occurred in 23 patients follow-
ing discontinuation of FBT alone/in combination with 
other opioids. Overall, 70 patients (11%) discontinued 
from long-term follow up because of AEs.35
conclusion
OraVescent technology enhances the oral dissolution 
and buccal absorption of fentanyl. This coupling of 
increased solubility and mucosal absorption facilitates 
rapid uptake of fentanyl into the bloodstream, reduc-
ing gastrointestinal absorption and successfully mini-
mizing extensive first-pass metabolism. The resulting 
pharmacokinetic profile of FBT is characterized by 
greater  bioavailability  and  a  higher  early  systemic 
exposure compared with the earlier OTFC formula-
tion. This technology could be used to enhance the 
delivery  of  other  drugs  that  are  pH-dependent  for 
solubilization and absorption through a cellular mem-
brane, such as the buccal mucosa.
In clinical studies of opioid-tolerant patients with 
cancer-related and noncancer-related BTP, FBT has 
provided consistent and clinically relevant improve-
ments in PI and PR relative to placebo, with a safety 
and tolerability profile that is generally typical of that 
observed with other potent opioids.
Recently, other technologies have also utilized the 
buccal and sublingual mucosa for delivery of fentanyl 
for the treatment of BTP. For example, a sublingual 
orally  disintegrating  tablet  has  been  formulated  to 
distribute an ordered mixture of fentanyl combined 
with soluble carrier particles,36 and a soluble film has 
been developed to deliver fentanyl by adhering to the 
buccal mucosa.37
Effective  management  of  BTP  requires  an  effi-
cient and rapid onset of analgesia. The pharmacoki-
netic properties of FBT allow for meaningful clinical 
  efficacy, with an onset of action that closely matches 
the onset of BTP. As with any schedule II controlled 
substance, the risk of abuse, misuse, and diversion 
must be carefully monitored and managed.
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